Following a barrage of letters from President Donald Trump urging 17 large pharmaceutical companies to implement Most Favored ...

Genmab and AbbVie are taking key steps toward moving their blood cancer drug Epkinly into earlier lines of treatment in ...

In line with the Trump administration’s goal to curb the United States’ reliance on overseas drug manufacturing, the FDA has ...

Otte took on the title in February, the culmination of nearly 25 years spent with the Danish drugmaker. As of his departure ...

Contract Development and Manufacturing Organizations (CDMOs) have carved out a lucrative niche within the biopharma industry, ...

CorMedix projects Melinta products will generate between $125 million and $135 million in revenue this year. The company also ...

Lilly has been chasing—and gaining on—its chief metabolic medicine rival Novo Nordisk and its counterpart GLP-1s Ozempic and ...

The FDA has removed a pause in the use of Valneva’s chikungunya vaccine in older adults while tweaking the shot’s label with stricter language.

Vor Bio has handed Dallan Murray a swift return to the workforce. | Vor Bio has handed Dallan Murray a swift return to the ...

Aurobindo will shell out $250 million to acquire drugmaker Lannett, shoring up the Indian drugmaker’s footprint in the U.S.

Garonit Pharmaceutical, an India-based API maker, plans to build a $46.1 million production plant in New York to produce ...

Merck pulled off its $10 billion buyout of Verona Pharma last month with little of the wheeling and dealing that typically ...